Laura T Dickens1, Lisa R Letourneau2, May Sanyoura2, Siri Atma W Greeley2, Louis H Philipson2, Rochelle N Naylor2. 1. Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, Kovler Diabetes Center, University of Chicago, 5841 South Maryland Ave., MC 1027, Chicago, IL, 60637, USA. Laura.Dickens@uchospitals.edu. 2. Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, Kovler Diabetes Center, University of Chicago, 5841 South Maryland Ave., MC 1027, Chicago, IL, 60637, USA.
Abstract
AIMS: GCK-MODY is characterized by mild hyperglycemia. Treatment is not required outside of pregnancy. During pregnancy, insulin treatment is recommended if second trimester fetal ultrasound monitoring shows macrosomia, suggesting the fetus has not inherited the GCK gene. There are limited data about GCK-MODY management in pregnancy. The aim of this study was to examine clinical management and pregnancy outcomes amongst women with a known diagnosis of GCK-MODY. METHODS: In this observational, cross-sectional study, a survey was distributed via Redcap to women ≥ 18 years enrolled in the University of Chicago Monogenic Diabetes Registry (n = 94). All or part of the survey was completed by 54 women (128 pregnancies). RESULTS: There were 78 term births (61%), 15 pre-term births (12%), and 24 miscarriages (19%). Of the 39 pregnancies where insulin was given, 22 (56%) had occasional or frequent hypoglycemia including 9 with severe hypoglycemia. Average birth weight for full-term GCK-affected infants was significantly less in cases of maternal insulin treatment versus no treatment (2967 and 3725 g, p = 0.005). For GCK-unaffected infants, conclusions are limited by small sample size but large for gestational age (LGA) was common with maternal insulin treatment (56%) and no treatment (33%), p = 0.590. CONCLUSIONS: The observed miscarriage rate was comparable to the background US population rate (15-20%). Patients treated with insulin experienced a 23% incidence of severe hypoglycemia and lower birth weights were observed in the insulin-treated, GCK-affected neonates. These data support published guidelines of no treatment if the fetus is suspected to have inherited GCK-MODY and highlight the importance of additional studies to determine optimal pregnancy management for GCK-MODY, particularly among unaffected fetuses.
AIMS: GCK-MODY is characterized by mild hyperglycemia. Treatment is not required outside of pregnancy. During pregnancy, insulin treatment is recommended if second trimester fetal ultrasound monitoring shows macrosomia, suggesting the fetus has not inherited the GCK gene. There are limited data about GCK-MODY management in pregnancy. The aim of this study was to examine clinical management and pregnancy outcomes amongst women with a known diagnosis of GCK-MODY. METHODS: In this observational, cross-sectional study, a survey was distributed via Redcap to women ≥ 18 years enrolled in the University of Chicago Monogenic Diabetes Registry (n = 94). All or part of the survey was completed by 54 women (128 pregnancies). RESULTS: There were 78 term births (61%), 15 pre-term births (12%), and 24 miscarriages (19%). Of the 39 pregnancies where insulin was given, 22 (56%) had occasional or frequent hypoglycemia including 9 with severe hypoglycemia. Average birth weight for full-term GCK-affected infants was significantly less in cases of maternal insulin treatment versus no treatment (2967 and 3725 g, p = 0.005). For GCK-unaffected infants, conclusions are limited by small sample size but large for gestational age (LGA) was common with maternal insulin treatment (56%) and no treatment (33%), p = 0.590. CONCLUSIONS: The observed miscarriage rate was comparable to the background US population rate (15-20%). Patients treated with insulin experienced a 23% incidence of severe hypoglycemia and lower birth weights were observed in the insulin-treated, GCK-affected neonates. These data support published guidelines of no treatment if the fetus is suspected to have inherited GCK-MODY and highlight the importance of additional studies to determine optimal pregnancy management for GCK-MODY, particularly among unaffected fetuses.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Siri Atma W Greeley; Rochelle N Naylor; Lindsay S Cook; Susan E Tucker; Rebecca B Lipton; Louis H Philipson Journal: J Diabetes Sci Technol Date: 2011-07-01
Authors: Ali J Chakera; Victoria L Carleton; Sian Ellard; Jencia Wong; Dennis K Yue; Jason Pinner; Andrew T Hattersley; Glynis P Ross Journal: Diabetes Care Date: 2012-07-06 Impact factor: 19.112
Authors: Amanda Stride; Beverley Shields; Olivia Gill-Carey; Ali J Chakera; Kevin Colclough; Sian Ellard; Andrew T Hattersley Journal: Diabetologia Date: 2013-10-04 Impact factor: 10.122
Authors: Soo Heon Kwak; Camille E Powe; Se Song Jang; Michael J Callahan; Sarah N Bernstein; Seung Mi Lee; Sunyoung Kang; Kyong Soo Park; Hak C Jang; Jose C Florez; Jong-Il Kim; Jong Hee Chae Journal: J Clin Endocrinol Metab Date: 2021-08-18 Impact factor: 5.958
Authors: Alice E Hughes; Elisa De Franco; Evgenia Globa; Nataliya Zelinska; Dörte Hilgard; Popi Sifianou; Andrew T Hattersley; Sarah E Flanagan Journal: Pediatr Diabetes Date: 2021-06-10 Impact factor: 3.409
Authors: Matthew C Riddle; Louis H Philipson; Stephen S Rich; Annelie Carlsson; Paul W Franks; Siri Atma W Greeley; John J Nolan; Ewan R Pearson; Philip S Zeitler; Andrew T Hattersley Journal: Diabetes Care Date: 2020-12 Impact factor: 19.112